- Entire Pipeline
- Discovery & Early Development
- Pre-clinical & Clinical Development
- Limited Market Availability
Displaying 161 - 170 of 243
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
Development Phase: Limited Market Availability
Alternative Name: ZK 98.299; ZK 98 299
User: Female
Hormonal: Yes
Developer: Schering AG
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: University of Washington, GlaxoSmithKline, NICHD
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: NIAID, NICHD, Origami Healthcare Products, Inc., Strata Various Product Design
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Barrier, Vaginal Ring
Developer: Dare BioScience Inc.
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Barrier
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Innolytics LLC
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Proprotein convertase 6
Target
Hormonal: No
Developer: CONRAD, Prince Henry's Institute of Medical Research, Australia
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Pages
Displaying 41 - 50 of 70
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Merck
Development Stage: Prototype Development
Alternative Name: Metalloprotease
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University
Development Stage: Target Validation
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Microchips Biotech, Inc.
Development Stage: Prototype Development
Target
User: Male
Hormonal: No
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Target Validation
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Washington University
Development Stage: Compound ID/Selection
Alternative Name: Lavax Vaginal Suppository
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: Lavax
Development Stage: Lead Optimization
User: Male
Hormonal: No
Delivery Method: Oral
Developer: North Shore University Hospital in New York
Development Stage: Lead Optimization
Alternative Name: Nomegestrol acetate (NOMAC) vaginal ring
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Developer: Merck
Development Stage: Prototype Development
User: Female, Male
Duration Type: Short-acting, Pericoital
Delivery Method: Injectable, Vaginal, Other, Other
Development Stage: Lead Optimization
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Lead Optimization
Pages
Displaying 31 - 40 of 121
Alternative Name: Estetrol (E4) + Drospirenone (DRSP) Combined Pill
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Mithra
Development Stage: Phase III
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Hera Health Solutions
Development Stage: Pre-clinical
Alternative Name: EVE-106; EVE106; ethinylestradiol prodrugs
User: Female
Hormonal: Yes
Developer: Evestra, Inc.
Development Stage: Pre-clinical
Alternative Name: Etonogestrel (ENG) + Ethinyl Estradiol (EE) Vaginal Ring; EVE112
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Evestra, Inc., Gedeon Richter Plc.
Development Stage: Phase III
Alternative Name: Antiestrogen ICI 182780; Fulvestrant
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: Femasys Inc
Development Stage: Phase I
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Injectable
Developer: University of Washington, Focused Scientific
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: University of Mumbai
Development Stage: Pre-clinical
Alternative Name: Single Rod GES Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Phase III
Alternative Name: GES VR
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal Ring
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Pre-clinical
Pages
Displaying 51 - 52 of 52
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed
Pages
